



Ospolot® a more acceptable anticonvulsant

"A clinical trial with Sulthiame (OSPOLOT) was undertaken in 45 long-standing epileptic subnormal patients, complicated by behaviour and psychotic disorders ... 64 per cent, showed overall clinical improvement. There was a reduction in frequency of seizures in 71 per cent, and complete relief in 38 per cent ... Side effects were few and minimal."

Brit. J. Psychiat. (1966), 112, 621-628

FBA PI U.K. Su

FBA PHARMACEUTICALS LTD., Haywards Heath, Sussex. U.K. Subsidiary of BAYER GERMANY & Registered trade mark of BAYER GERMANY